RNAC

Cartesian Therapeutics, Inc.

Nasdaq · Pharmaceutical Preparations · Inc. DE · CIK 0001453687
$9.51 +17.99% $279.4M
High Impact Filing (7/10)5 New Institutional Positions3 Institutional Exits
Vol
Market Cap$279.4M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (93%)
Inst. Holders32 funds
Inst. Value$19.3M
Inst. Activity5 buys / 3 sells
Reddit Sentiment67° Warm
SEC Reports1
Press Releases1
Exchange Nasdaq·Sector Pharmaceutical Preparations·Inc. DE·CIK 0001453687·Prev Close $8.06

Recent Activity

Jun 12, 2026 other
Cartesian Therapeutics Announces New Employment Inducement Grant
<p align="justify">FREDERICK, Md., June 12, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc.
Jun 5, 2026 SEC
Cartesian Therapeutics secured a senior secured credit facility from K2 HealthVentures for up to $150 million, with an i
8-K — Impact 7/10
Apr 2, 2026 Insider
Kalayoglu Murat acquired via exercise 758,001 shares
10%+ Owner
Apr 2, 2026 Insider
Kalayoglu Murat acquired via exercise 22,740.03 shares
10%+ Owner
Apr 2, 2026 Insider
Hoge Elizabeth acquired via exercise 758,001 shares
10%+ Owner
Inst.
FMR LLC — TRIM
799,743 shares ($4.9M)
Inst.
MARSHALL WACE, LLP — ADD
251,115 shares ($1.5M)
May 26, 2026 Press
Cartesian Therapeutics secured a $150M non-dilutive credit facility from K2 HealthVentures, with an initial $50M tranche
Impact 7/10

Price Targets

$34.57 +263.5% upside Strong Buy
Current $9.51 Low $16.00 Median $39.00 High $44.00 7 analysts
$16.00 $44.00

Analyst Ratings

Strong Buy93% buy · 14 analysts
5Strong Buy
8Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
DateFirmActionRating
Jun 10, 2026 Wedbush REITERATE Outperform → Outperform
Jun 9, 2026 Needham REITERATE Buy → Buy
Jun 9, 2026 BTIG REITERATE Buy → Buy
May 27, 2026 Wedbush REITERATE Outperform → Outperform
May 26, 2026 Needham MAINTAIN Buy → Buy

Earnings Estimates

PeriodEPS Est.RangeGrowth#
Current Q $-0.65 ▲ +4.4% $-0.65 — $-0.65 16% YoY 1
Next Q $-0.69 ▼ -53.3% $-0.69 — $-0.69 6% YoY 1
Current FY $-3.35 ▼ -55.8% $-3.35 — $-3.35 33% YoY 1
Next FY $-2.68 ▼ -58.6% $-2.68 — $-2.68 20% YoY 1

Top Institutional Holders

FundValueMove
ROYAL BANK OF CANADADOUBLED
FMR LLC$4.9MTRIM
BlackRock, Inc.$3.7MADD
VANGUARD CAPITAL MANAGEMENT LLC$2.5M
MARSHALL WACE, LLP$1.5MADD

Recent Insider Trades

DateInsiderTypeValue
Apr 2, 2026Kalayoglu MuratM$0.00
Apr 2, 2026Kalayoglu MuratM$0.00
Apr 2, 2026Hoge ElizabethM$0.00
Apr 2, 2026Hoge ElizabethM$0.00
Mar 13, 2026Singer MichaelG$0.00

Reddit Sentiment

67°
Warm
Bearish Neutral Bullish
2 mentions 2 bullish 0 bearish
32 institutional holders with $19.3M total value (3,149,770 shares) as of 2026-Q1. Top holders: ROYAL, FMR, BlackRock,. Net buying activity: 5 institutions added/increased vs 3 reduced.

Top Institutional Holders — 2026-Q1

#FundSharesValue% of TrackedLast Move
1ROYAL BANK OF CANADA70$0.000.0%DOUBLED +667.3%
2FMR LLC799,743$4.9M25.5%TRIM -41.5%
3BlackRock, Inc.599,108$3.7M19.1%ADD +55.7%
4VANGUARD CAPITAL MANAGEMENT LLC407,597$2.5M13.0%
5MARSHALL WACE, LLP251,115$1.5M8.0%ADD +41.0%
6Erste Asset Management GmbH221,705$1.3M6.7%ADD +49.8%
7STATE STREET CORP200,337$1.2M6.4%
8TWO SIGMA INVESTMENTS, LP167,313$1.0M5.3%
9CITADEL ADVISORS LLC110,128$677.3K3.5%TRIM -41.7%
10VANGUARD FIDUCIARY TRUST CO70,296$432.3K2.2%
11RENAISSANCE TECHNOLOGIES LLC67,300$413.9K2.1%ADD +63.7%
12VANGUARD PORTFOLIO MANAGEMENT LLC60,583$372.6K1.9%
13Nuveen, LLC37,451$230.3K1.2%ADD +52.9%
14GOLDMAN SACHS GROUP INC30,927$190.2K1.0%
15CHARLES SCHWAB INVESTMENT MANAGEMENT INC24,929$153.3K0.8%ADD +40.7%
16ALLIANCEBERNSTEIN L.P.12,765$92.0K0.5%
17MORGAN STANLEY14,805$91.1K0.5%TRIM -36.4%
18AMERIPRISE FINANCIAL INC13,416$82.5K0.4%TRIM -32.3%
19SEI INVESTMENTS CO12,764$78.5K0.4%
20RHUMBLINE ADVISERS12,360$76.0K0.4%ADD +27.5%

Recent Position Changes

FundActionPrev SharesCurr SharesChange %ValueQuarter
FMR LLCTRIM1,366,989799,743-41.5%$4.9M2026-Q1
MARSHALL WACE, LLPADD178,140251,115+41.0%$1.5M2026-Q1
RENAISSANCE TECHNOLOGIES LLCADD41,10067,300+63.7%$413.9K2026-Q1
Nuveen, LLCADD24,49737,451+52.9%$230.3K2026-Q1
MORGAN STANLEYTRIM23,29414,805-36.4%$91.1K2026-Q1
AMERIPRISE FINANCIAL INCTRIM19,80613,416-32.3%$82.5K2026-Q1
CWM, LLCDOUBLED1914,636+2327.2%$28.5K2026-Q1
PNC FINANCIAL SERVICES GROUP, INC.DOUBLED536+620.0%$221.002026-Q1
FMR LLCTRIM2,155,7831,366,989-36.6%$9.9M2025-Q4
MARSHALL WACE, LLPDOUBLED84,806178,140+110.1%$1.3M2025-Q4
BANK OF AMERICA CORP /DE/DOUBLED14,069113,092+703.8%$815.4K2025-Q4
WELLS FARGO & COMPANY/MNADD7,88411,762+49.2%$84.8K2025-Q4
CITADEL ADVISORS LLCTRIM120,87470,524-41.7%$720.8K2025-Q3
MORGAN STANLEYTRIM29,21318,974-35.0%$193.9K2025-Q3
BARCLAYS PLCTRIM30,67517,842-41.8%$182.3K2025-Q3
WELLS FARGO & COMPANY/MNADD5,8337,884+35.2%$80.6K2025-Q3
Mirae Asset Global Investments Co., Ltd.NEAR_EXIT4,7181,005-78.7%$10.3K2025-Q3
Russell Investments Group, Ltd.DOUBLED55767+1294.5%$7.8K2025-Q3
Zurcher Kantonalbank (Zurich Cantonalbank)TRIM640439-31.4%$4.5K2025-Q3
NISA INVESTMENT ADVISORS, LLCDOUBLED43107+148.8%$1.1K2025-Q3
CWM, LLCTRIM553254-54.1%$3.002025-Q3
MARSHALL WACE, LLPDOUBLED38,60582,630+114.0%$858.5K2025-Q2
ROYAL BANK OF CANADADOUBLED2,38518,300+667.3%$190.0K2025-Q2
UBS Group AGTRIM31,11813,206-57.6%$137.2K2025-Q2
BARCLAYS PLCDOUBLED14,36930,675+113.5%$318.002025-Q2
3 unique insiders with 5 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).

Insider Transactions

DateInsiderTitleTypeSharesPriceValue
Apr 2, 2026Kalayoglu Murat10%+ OwnerEXERCISE758,001
Apr 2, 2026Kalayoglu Murat10%+ OwnerEXERCISE22,740.03
Apr 2, 2026Hoge Elizabeth10%+ OwnerEXERCISE758,001
Apr 2, 2026Hoge Elizabeth10%+ OwnerEXERCISE22,740.03
Mar 13, 2026Singer MichaelDirectorGIFT6,555
1 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 0 neutral. Avg impact: 7.0/10.
Current analyst consensus: Strong Buy (93% buy). Based on 14 analysts: 5 strong buy, 8 buy, 1 hold, 0 sell, 0 strong sell.

Analyst Price Targets

$34.57 mean target +263.5% upside Strong Buy (1.13)
$16.00 Low $44.00 High
MetricValue
Current Price$9.51
Target Low$16.00
Target Mean$34.57
Target Median$39.00
Target High$44.00
# Analysts7
RecommendationStrong Buy (1.13)

Earnings Estimates & Revisions

PeriodEPS AvgEPS LowEPS HighEPS Growth30d Rev.Up/DownRev. AvgRev. GrowthAnalysts
Current Q
2026-06-30
$-0.65 $-0.65 $-0.65 15.8% +4.4% 1↑ 0↓ $0.0B -45.9% 1
Next Q
2026-09-30
$-0.69 $-0.69 $-0.69 5.6% -53.3% 0↑ 1↓ $0.0B -64.3% 1
Current FY
2026-12-31
$-3.35 $-3.35 $-3.35 32.9% -55.8% 0↑ 1↓ $0.0B -80.3% 1
Next FY
2027-12-31
$-2.68 $-2.68 $-2.68 20.0% -58.6% 0↑ 1↓ $0.0B -27.3% 1

Current Quarter EPS Revision History

TimepointEPS EstimateChange
Current$-0.650
7d ago$-0.770+0.120
30d ago$-0.680+0.030
60d ago$-0.680+0.030
90d ago$0.000-0.650
5 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 0 initiations.

Individual Analyst Actions

DateAnalyst FirmActionPrevious RatingNew Rating
Jun 10, 2026 Wedbush REITERATE Outperform Outperform
Jun 9, 2026 Needham REITERATE Buy Buy
Jun 9, 2026 BTIG REITERATE Buy Buy
May 27, 2026 Wedbush REITERATE Outperform Outperform
May 26, 2026 Needham MAINTAIN Buy Buy
May 12, 2026 HC Wainwright & Co. MAINTAIN Buy Buy
May 1, 2026 Wedbush REITERATE Outperform Outperform
Mar 10, 2026 Wedbush REITERATE Outperform Outperform
Mar 9, 2026 Cantor Fitzgerald UPGRADE Neutral Overweight
Mar 9, 2026 Needham REITERATE Buy Buy
Jan 9, 2026 Needham MAINTAIN Buy Buy

Monthly Consensus History

PeriodStrong BuyBuyHoldSellStrong SellBuy %Distribution
Jun 1, 20265810093%
May 1, 20265820087%
Apr 1, 20265730080%
Mar 1, 20265730080%
Feb 1, 20265730080%
Jan 1, 20265730080%
Strong BuyBuyHoldSellStrong Sell

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

67°
Warm
Bearish Neutral Bullish
2 mentions 2 bullish 0 bearish 2 time periods

Reddit Sentiment History

DateMentionsSentimentBullishBearishThreads
May 29, 2026160° Warm101
May 29, 2026160° Warm101

Recent Reddit Threads

r/wallstreetbets Bullish 14d 17h ago
🚀 $RNAC: mRNA Biotech with Q1 Catalyst & Fresh Cash. 5-10x Potential 💎 🙌
▲ 1 💬 0 ⚡ 0.5
Jun 12, 2026
other
Cartesian Therapeutics Announces New Employment Inducement Grant
<p align="justify">FREDERICK, Md., June 12, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-st
May 26, 2026
fda
Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027
<p align="center"><em>Secured up to $150 million of non-dilutive financing from K2 HealthVentures; funding of $50 million from initial tranche extends
May 12, 2026
other
Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
<p align="justify">FREDERICK, Md., May 12, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-sta
May 7, 2026
earnings_calendar
RNAC Q1 2026 Earnings Scheduled — 2026-05-07
May 4, 2026
other
Cartesian Therapeutics Announces New Employment Inducement Grants
<p align="justify">FREDERICK, Md., May 04, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-sta
Apr 30, 2026
earnings
Cartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
<p align="center"><em>Enrollment continues to progress in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis </em></p>
Apr 2, 2026
other
Cartesian Therapeutics Announces New Employment Inducement Grants
<p align="justify">FREDERICK, Md., April 02, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-s
Mar 11, 2026
earnings_calendar
RNAC Q4 2025 Earnings After Market Close — 2026-03-11
Mar 9, 2026
earnings
Cartesian Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update
<p align="center"><em>Enrollment continues to progress in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis</em></p>
Mar 5, 2026
earnings_calendar
RNAC Q4 2025 Earnings After Market Close — 2026-03-05